Tag: Lonza
Bioconjugation Technology Selection during Early-Stage Development – A Strategy to Streamline...
Abstract
Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone...
Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering
In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).
Simris and Lonza Sign Partnership Agreement to Promote Novel Payload Technology
Sweden-based Simris Group, a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, has signed a strategic collaboration...
Lonza Continues Investment in China with New Manufacturing Services Facility...
Lonza, a global contract development and manufacturing organization (CDMO), in a statement, said that it will invest to establish drug product manufacturing capabilities at...
Lonza Expands its Bioconjugation Facility with Two Additional Manufacturing Suites and...
Lonza is expanding its bioconjugation capabilities at its Visp in Switzerland. The expansion adds two production suites to the existing conjugation facility providing development...
Lonza to Provide Customer-Dedicated Suites for Commercialization of Bioconjugates
Lonza, in a statement, confirmed signing a strategic collaboration for bioconjugation with a global biopharma company.
Under the terms of the agreement, Lonza will construct...
Lonza Opens News Facility for ADC Payload Manufacturing Following a Tailored...
Lonza, a specialty Contract Development and Manufacturing partner for biopharmaceutical companies, inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload)...
Navrogen and Levena to Develop Novel ADC for the Treatment of...
Biopharmaceutical company Navrogen, specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, have agreed to collaborate in developing an antibody-drug conjugate...
5 Things You Need To Know This Week About ADCs –...
This is the second article in my series of updates about the goings on in the world of ADCs over the last two weeks....
Lonza’s Collaborative Innovation Center Helps Rethink Development and Manufacturing
A new Collaborative Innovation Center in the Haifa Life Science Park, Haifa, Israel, developed and managed by Lonza Pharma & Biotech, will acts as...
